Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R01)

The summary for the Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R01): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), encourages Research Project Grant (R01) applications from institutions/organizations that propose to evaluate the pharmacokinetics of anti-tuberculosis (anti-TB) drugs and pharmacokinetic drug interactions between anti-TB drugs and anti-HIV medications, and to potentially provide preliminary data regarding the effect of such pharmacokinetic parameters on the outcome of treatment in children with HIV/TB co-infection.Pediatric research in these areas lags far behind that in adults due to the many challenges surrounding the diagnosis and management of TB disease in children. Research related to the treatment of TB in the context of pediatric HIV/TB co-infection is urgently needed.This FOA will support grants to define appropriate dosing of anti-TB agents in HIV-infected children and that will generate knowledge regarding the optimization of management of TB/HIV co-infection in children, including the management of central nervous system (CNS) involvement with TB through the evaluation of CNS penetration of anti-TB agents in the context of antiretroviral therapy. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism and is issued in parallel with an FOA of identical scientific scope, RFA HD-09-016 that solicits applications under the R21 grant mechanism. Funds Available and Anticipated Number of Awards. The NICHD intends to commit $1.15 million (total costs), and NIMH intends to commit $350,000 (total costs) in FY 2010 to support one to three meritorious applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Federal Grant Title: Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R01)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HD-09-015
Type of Funding: Grant
CFDA Numbers: 93.242
CFDA Descriptions: Mental Health Research Grants
Current Application Deadline: Aug 24, 2010
Original Application Deadline: Aug 24, 2010
Posted Date: Mar 03, 2010
Creation Date: Mar 04, 2010
Archive Date: Sep 24, 2010
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R...
Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R...
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Ad...
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com